You have raised some questions with your comparison with POH and PRR. Both these companies have, give or take 1B shares on issue. This situation usually comes about because companies have lost there way sometime in the past. I`m sure JV could give us a blow by blow re POH and probably CZD. There is a difference with CZD in part because of shareholder involvement. We have 350m shares on issue. A little over, at last count 21.4% are owned by either Board or senior management. This is proably unique in the Biotech sector. Add to that the likes of JV and myself with 2m+ holders that believe we now finally have something of value and the register becomes a little more stable. This situation re the issued capital gives the Board more flexibilty when it come to extracting value from any CR that might be required on the back of success from trials now under way. I haven`t been happy with the wording of some of the announcements and this has been conveyed either directly or via HC. There is a balance between saving on unecessary expense at the administrative end preserving funds for the proving of the technology. The present Board have made the call and if wrong will cost them as much as us, maybe more.
I believe the overhang has gone and am happy to have taken some of the stock, will be in the market tomorrow as I agree with gvancath that sub .05c or even higher is good value considering where we are at in terms of proving the tech. You probably do as well with your $12m market cap comparison.
Cheers
G
CZD Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held